Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $21.46 + 0.65 (3.12%)
ExchangeNASDAQ
Volume128,652
Today's Open$20.86
Previous Close$20.81
Data as of 08/21/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $21.46 with a 52 week high of $23.66 and a 52 week low of $7.60.

Recent News

August 07, 2018

Nuvectra™ Reports Second Quarter 2018 Financial Results

Reports Record Algovita® Sales of $11.5 million, Up 110% YoY PLANO, Texas, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended June 30, 2018. Highlights Reported record consolidated revenues of $13.1 million for the second quarter 2018. Reached approximately 60 active territories for U.S. Algovita. Submitted Virtis™ response to FDA, initiated new 180-day r

Read More >

August 02, 2018

Nuvectra™ Appoints Neuromodulation Veteran Ben Tranchina as Chief Technology Officer

PLANO, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the appointment of Ben Tranchina as Chief Technology Officer (CTO), effective August 24, 2018. Mr. Tranchina has over 25 years of industry experience and most relevantly served as VP, Product Development at St. Jude Medical, where he led the development of the company’s neuromodulation portfolio, following his time at Advanced Neuromodulation Systems,

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
There are currently no events scheduled.